T1	p 335 361	healthy young subjects was
T2	p 431 461	Five groups of 8 subjects each
T3	p 578 591	for 14 days .
T4	p 634 650	treated subjects
T5	p 1612 1615	low
T6	i 181 222	potent cholesteryl ester transfer protein
T7	i 230 253	) inhibitor torcetrapib
T8	i 481 519	placebo ( n=2 ) or torcetrapib ( n=6 )
T9	i 542 545	120
T10	i 559 562	120
T11	i 590 603	. Torcetrapib
T12	i 1187 1201	Apolipoprotein
T13	o 278 324	high-density lipoprotein cholesterol ( HDL-C )
T14	o 613 622	tolerated
T15	o 693 727	plasma drug levels with inhibition
T16	o 1001 1025	Total plasma cholesterol
T17	o 1129 1164	low-density lipoprotein cholesterol
T18	o 1187 1205	Apolipoprotein A-I
T19	o 1349 1361	triglyceride
T20	o 1379 1401	nonHDL plasma fraction